Jennifer Jarrett's most recent trade in Galecto Inc was a trade of 1,500,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | Jennifer Ann Jarrett | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2026 | 1,500,000 | 1,500,000 | - | - | Stock Option (right to buy) | |
| Galecto Inc | Jennifer Ann Jarrett | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2026 | 500,000 | 500,000 | - | 0 | Common Stock | |
| Syndax Pharma Inc | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 24,000 | 114,000 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2026 | 126,000 | 126,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2026 | 31,000 | 224,024 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.88 per share. | 16 Dec 2025 | 11,225 | 203,007 (0%) | 0% | 21.9 | 245,651 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.16 per share. | 16 Dec 2025 | 9,983 | 193,024 (0%) | 0% | 22.2 | 221,218 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 50,291 | 80,583 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.97 per share. | 07 Nov 2025 | 50,291 | 214,232 (0%) | 0% | 19.0 | 954,066 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 07 Nov 2025 | 50,291 | 264,523 (0%) | 0% | 1.2 | 61,737 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 37,792 | 130,874 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.05 per share. | 06 Oct 2025 | 37,792 | 214,232 (0%) | 0% | 15.0 | 568,611 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 06 Oct 2025 | 37,792 | 252,024 (0%) | 0% | 1.2 | 46,393 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 06 Oct 2025 | 12,500 | 226,732 (0%) | 0% | 1.2 | 15,345 | Common Stock |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 12,500 | 168,666 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 14.54 per share. | 06 Oct 2025 | 12,500 | 214,232 (0%) | 0% | 14.5 | 181,801 | Common Stock |
| Sagimet Biosciences Inc (Class A) | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 27,268 | 27,268 | - | - | Stock Option (Right to Buy) | |
| Zura Bio Ltd (Class A) | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 51,000 | 51,000 | - | - | Share Option (Right to Buy) | |
| Syndax Pharma Inc | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 25,000 | 90,000 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 50,000 | 213,369 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | 15 Dec 2024 | 27,501 | 163,369 (0%) | 0% | 16.1 | 442,216 | Common Stock | |
| Zura Bio Ltd (Class A) | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 117,000 | 117,000 | - | - | Share Option (Right to Buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | 15 Sep 2024 | 12,670 | 190,394 (0%) | 0% | 18.0 | 227,427 | Common Stock | |
| Sagimet Biosciences Inc (Class A) | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 113,895 | 113,895 | - | - | Stock Option (Right to Buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | 15 Jun 2024 | 12,670 | 203,064 (0%) | 0% | 17.0 | 215,010 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | 27 Mar 2024 | 11,551 | 215,253 (0%) | 0% | 17.5 | 202,720 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | 18 Mar 2024 | 12,153 | 228,100 (0%) | 0% | 17.8 | 216,810 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Chief Operating Officer | 18 Mar 2024 | 1,296 | 226,804 (0%) | 0% | 18.6 | 24,132 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett Ann | Chief Operating Officer | 26 Feb 2024 | 34,070 | 240,253 (0%) | 0% | 20.1 | 685,148 | Common Stock | |
| Arcus Biosciences Inc | Ann Jennifer Jarrett | Chief Operating Officer | 26 Feb 2024 | 24,555 | 274,323 (0%) | 0% | 20.1 | 492,819 | Common Stock | |
| Syndax Pharma Inc | Ann Jarrett Jennifer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 17,000 | 65,000 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 23 Jan 2024 | 162,400 | 162,400 | - | - | Stock Option (right to buy) | ||
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 23 Jan 2024 | 40,000 | 298,878 (0%) | 0% | 0 | Common Stock | ||
| Arcus Biosciences Inc | Jarrett Ann Jennifer | Director, Chief Operating Officer | 22 Dec 2023 | 21,521 | 258,878 (0%) | 0% | 17.8 | 382,213 | Common Stock | |
| Arcus Biosciences Inc | Ann Jarrett Jennifer | Director, Chief Operating Officer | 18 Dec 2023 | 11,492 | 280,399 (0%) | 0% | 18.1 | 207,890 | Common Stock | |
| Arcus Biosciences Inc | Ann Jennifer Jarrett | Director, Chief Operating Officer | 18 Dec 2023 | 11,250 | 291,891 (0%) | 0% | 17.7 | 199,575 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 22 Sep 2023 | 21,369 | 302,691 (0%) | 0% | 20.0 | 427,166 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 18 Sep 2023 | 12,506 | 324,060 (0%) | 0% | 20.4 | 255,122 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 28 Jul 2023 | 45,000 | 336,566 (0%) | 0% | 20.3 | 911,250 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 22 Jun 2023 | 12,437 | 381,566 (0%) | 0% | 19.1 | 237,795 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Jun 2023 | 12,563 | 394,003 (0%) | 0% | 19.3 | 243,094 | Common Stock | |
| Zura Bio Ltd (Class A) | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 7,652 | 7,652 | - | - | Employee Share Option (Right to Buy) | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Mar 2023 | 8,729 | 406,217 (0%) | 0% | 16.8 | 146,734 | Common Stock | |
| Syndax Pharma Inc | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 16,000 | 48,000 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 26 Jan 2023 | 1,600 | 414,946 (0%) | 0% | 23.5 | 37,632 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 26 Jan 2023 | 300 | 416,546 (0%) | 0% | 23.6 | 7,068 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 23 Jan 2023 | 185,900 | 185,900 | - | - | Stock Option (right to buy) | ||
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 23 Jan 2023 | 45,800 | 416,846 (0%) | 0% | 0 | Common Stock | ||
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Dec 2022 | 13,879 | 150,212 (0%) | 0% | 30.7 | 425,530 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Dec 2022 | 2,603 | 147,609 (0%) | 0% | 31.2 | 81,292 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Sep 2022 | 12,677 | 130,942 (0%) | 0% | 26.3 | 333,152 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Jun 2022 | 6,081 | 125,233 (0%) | 0% | 20.7 | 125,998 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Jun 2022 | 4,663 | 118,619 (0%) | 0% | 22.3 | 103,938 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Jun 2022 | 1,951 | 123,282 (0%) | 0% | 21.7 | 42,356 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 16 Mar 2022 | 9,617 | 105,978 (0%) | 0% | 31.6 | 304,090 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 08 Mar 2022 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | ||
| Arcus Biosciences Inc | Jennifer Ann Jarrett | Director, Chief Operating Officer | 08 Mar 2022 | 31,250 | 121,845 (0%) | 0% | 0 | Common Stock | ||
| Syndax Pharma Inc | Jennifer Ann Jarrett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 16,000 | 32,000 (0%) | 0% | 0 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Dec 2021 | 20,923 | 93,395 (0%) | 0% | 41.7 | 872,458 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Dec 2021 | 11,099 | 114,318 (0%) | 0% | 40.9 | 453,677 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Dec 2021 | 2,800 | 90,595 (0%) | 0% | 42.2 | 118,234 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Dec 2021 | 4,064 | 134,031 (0%) | 0% | 39.6 | 160,900 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Dec 2021 | 2,575 | 125,417 (0%) | 0% | 41.4 | 106,666 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Dec 2021 | 1,955 | 127,992 (0%) | 0% | 40.6 | 79,321 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Dec 2021 | 1,580 | 130,955 (0%) | 0% | 38.8 | 61,285 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Dec 2021 | 1,496 | 132,535 (0%) | 0% | 40.5 | 60,523 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Dec 2021 | 1,008 | 129,947 (0%) | 0% | 39.7 | 39,989 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Sep 2021 | 21,900 | 130,309 (0%) | 0% | 35.1 | 767,814 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Sep 2021 | 11,981 | 117,728 (0%) | 0% | 35.5 | 425,326 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Sep 2021 | 8,134 | 152,209 (0%) | 0% | 35.5 | 288,610 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Sep 2021 | 4,885 | 112,843 (0%) | 0% | 36.0 | 175,762 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 20 Sep 2021 | 600 | 129,709 (0%) | 0% | 35.7 | 21,402 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Jun 2021 | 4,863 | 135,343 (0%) | 0% | 23.7 | 115,156 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Jun 2021 | 3,809 | 140,365 (0%) | 0% | 24.1 | 91,911 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 16 Jun 2021 | 159 | 140,206 (0%) | 0% | 24.8 | 3,938 | Common Stock | |
| Arcus Biosciences Inc | Jennifer Jarrett | Director, Chief Operating Officer | 04 Jun 2021 | 1,044 | 119,174 (0%) | 0% | 24.9 | 26,006 | Common Stock |